FCs facilitate allogeneic HSC engraftment without acute GVHD
Engraftment . | n . | 30-d survival, % . | Donor chimerism at 3 mo, % . | GVHD clinical score . |
|---|---|---|---|---|
| Syngeneic HSC | 6 | 100 | - | 1.0 ± 0.3 |
| Allogeneic HSC + TBM | 10 | 10* | - | - |
| Allogeneic HSC + FC | 8 | 88.9 | 94.1 ± 1.8 | 1.25 ± 0.3 |
Engraftment . | n . | 30-d survival, % . | Donor chimerism at 3 mo, % . | GVHD clinical score . |
|---|---|---|---|---|
| Syngeneic HSC | 6 | 100 | - | 1.0 ± 0.3 |
| Allogeneic HSC + TBM | 10 | 10* | - | - |
| Allogeneic HSC + FC | 8 | 88.9 | 94.1 ± 1.8 | 1.25 ± 0.3 |
All HSC + TBM recipients died by 3 months